@article{ghuman_atomoxetine_2014,
	title = {Atomoxetine is a second-line medication treatment option for {ADHD}},
	volume = {17},
	issn = {1362-0347},
	url = {http://dx.doi.org/10.1136/eb-2014-101805},
	doi = {10.1136/eb-2014-101805},
	abstract = {Even though atomoxetine improved both inattentive and hyperactive
symptoms, response was lower than for stimulants and 40\% of participants
taking atomoxetine had significant residual ADHD symptoms. Compared with
placebo, a higher proportion of those taking atomoxetine had at least one
adverse effect, experienced more weight loss and discontinued study
participation.},
	number = {4},
	journal = {Evid. Based. Ment. Health},
	author = {Ghuman, Jaswinder K and Hutchison, Shari L},
	month = nov,
	year = {2014},
	note = {00000},
	keywords = {Sep 20 import, duplicate},
	pages = {108}
}

{"_id":"iRhbor6TmFcfzTTsn","bibbaseid":"ghuman-hutchison-atomoxetineisasecondlinemedicationtreatmentoptionforadhd-2014","downloads":0,"creationDate":"2018-04-27T04:04:44.551Z","title":"Atomoxetine is a second-line medication treatment option for ADHD","author_short":["Ghuman, J. K","Hutchison, S. L"],"year":2014,"bibtype":"article","biburl":"https://bibbase.org/zotero/davidlloyd33","bibdata":{"bibtype":"article","type":"article","title":"Atomoxetine is a second-line medication treatment option for ADHD","volume":"17","issn":"1362-0347","url":"http://dx.doi.org/10.1136/eb-2014-101805","doi":"10.1136/eb-2014-101805","abstract":"Even though atomoxetine improved both inattentive and hyperactive symptoms, response was lower than for stimulants and 40% of participants taking atomoxetine had significant residual ADHD symptoms. Compared with placebo, a higher proportion of those taking atomoxetine had at least one adverse effect, experienced more weight loss and discontinued study participation.","number":"4","journal":"Evid. Based. Ment. Health","author":[{"propositions":[],"lastnames":["Ghuman"],"firstnames":["Jaswinder","K"],"suffixes":[]},{"propositions":[],"lastnames":["Hutchison"],"firstnames":["Shari","L"],"suffixes":[]}],"month":"November","year":"2014","note":"00000","keywords":"Sep 20 import, duplicate","pages":"108","bibtex":"@article{ghuman_atomoxetine_2014,\n\ttitle = {Atomoxetine is a second-line medication treatment option for {ADHD}},\n\tvolume = {17},\n\tissn = {1362-0347},\n\turl = {http://dx.doi.org/10.1136/eb-2014-101805},\n\tdoi = {10.1136/eb-2014-101805},\n\tabstract = {Even though atomoxetine improved both inattentive and hyperactive\nsymptoms, response was lower than for stimulants and 40\\% of participants\ntaking atomoxetine had significant residual ADHD symptoms. Compared with\nplacebo, a higher proportion of those taking atomoxetine had at least one\nadverse effect, experienced more weight loss and discontinued study\nparticipation.},\n\tnumber = {4},\n\tjournal = {Evid. Based. Ment. Health},\n\tauthor = {Ghuman, Jaswinder K and Hutchison, Shari L},\n\tmonth = nov,\n\tyear = {2014},\n\tnote = {00000},\n\tkeywords = {Sep 20 import, duplicate},\n\tpages = {108}\n}\n\n","author_short":["Ghuman, J. K","Hutchison, S. L"],"key":"ghuman_atomoxetine_2014","id":"ghuman_atomoxetine_2014","bibbaseid":"ghuman-hutchison-atomoxetineisasecondlinemedicationtreatmentoptionforadhd-2014","role":"author","urls":{"Paper":"http://dx.doi.org/10.1136/eb-2014-101805"},"keyword":["Sep 20 import","duplicate"],"downloads":0},"search_terms":["atomoxetine","second","line","medication","treatment","option","adhd","ghuman","hutchison"],"keywords":["sep 20 import","duplicate"],"authorIDs":[],"dataSources":["pWG6kkFjeQheTxKbs"]}